Trevi Therapeutics Inc. TRVI
Super Investor & Insider
1
Fondi che lo detengono
#883
Rank consenso
1.4%
% dei portafogli
$38.2M
Valore detenuto
| Fondo | % portaf. | Attività | Azioni | Valore |
|---|---|---|---|---|
| Viking Global Investors · Viking Global Investors | 0.11% | — | 3,198,644 | $38.2M |
Fondi: 13F-HR alla SEC. Insider: acquisti (P) e vendite (S) in borsa da SEC EDGAR, ultimi 12 mesi.
About
Trevi Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing Haduvio, an oral extended-release formulation of nalbuphine, for treating chronic cough in patients with idiopathic pulmonary fibrosis, non-IPF interstitial lung disease, and refractory chronic cough. Haduvio…
SectorHealthcare
ExchangeNASDAQ
IndustryBiotechnology
CountryUnited States
Employees34
TickerTRVI
Statistics
Market Cap$2.10B
Revenue (TTM)$0
Net Income-$42.8M
Net Margin—
EPS$-0.32
P/E-42.03
P/S—
P/B9.39
EV/EBITDA-33.41
ROE-33.6%
Dividend Yield—
Price$16.35
Data: Twelve Data · Revenue = mcap / P/S